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Abstract
Background: The blood-brain tumor barrier (BTB) impedes the delivery of therapeutic agents to
brain tumors. While adequate delivery of drugs occurs in systemic tumors, the BTB limits delivery
of anti-tumor agents into brain metastases.
Results: In this study, we examined the function and regulation of calcium-activated potassium
(KCa) channels in a rat metastatic brain tumor model. We showed that intravenous infusion of
NS1619, a KCa channel agonist, and bradykinin selectively enhanced BTB permeability in brain
tumors, but not in normal brain. Iberiotoxin, a KCa channel antagonist, significantly attenuated
NS1619-induced BTB permeability increase. We found KCa channels and bradykinin type 2
receptors (B2R) expressed in cultured human metastatic brain tumor cells (CRL-5904, non-small
cell lung cancer, metastasized to brain), human brain microvessel endothelial cells (HBMEC) and
human lung cancer brain metastasis tissues. Potentiometric assays demonstrated the activity of KCa
channels in metastatic brain tumor cells and HBMEC. Furthermore, we detected higher expression
of KCa channels in the metastatic brain tumor tissue and tumor capillary endothelia as compared to
normal brain tissue. Co-culture of metastatic brain tumor cells and brain microvessel endothelial
cells showed an upregulation of KCa channels, which may contribute to the overexpression of KCa
channels in tumor microvessels and selectivity of BTB opening.
Conclusion: These findings suggest that KCa channels in metastatic brain tumors may serve as an
effective target for biochemical modulation of BTB permeability to enhance selective delivery of
chemotherapeutic drugs to metastatic brain tumors.
Background
The blood-brain barrier (BBB), formed by the capillary
endothelial cells surrounded by astrocytes, protects the
brain, but it also poses an obstacle for the delivery of ther-
apeutic molecules into the brain. Microvessels supplying
brain tumors retain some characteristics of the BBB and
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form a blood-brain tumor barrier (BTB). While adequate
delivery of chemotherapeutic drugs has been achieved in
systemic tumors, the BTB limits such delivery to brain
metastases. Therefore, understanding the biochemical
modulation of BBB and BTB is critical for developing strat-
egies to deliver therapeutic agents into metastatic brain
tumors.
During the past decade, various strategies have been used
to deliver therapeutic drugs selectively to brain tumors
and injured brain, including, biodegradable polymers
implanted into the tumor cavity [1], convection-enhanced
delivery [2,3], and BBB/BTB disruption [4,5]. Our labora-
tory has focused on pharmacologic modulations to
increase BTB permeability and increase delivery of thera-
peutic drugs selectively to brain tumors with little or no
drug delivery to normal brain tissue [6-9]. This strategy
exploits the function of certain vasomodulators that play
a key role in modulation of BBB/BTB permeability. It has
been demonstrated that bradykinin [10], leukotriene
(LTC4) [11-13], nitric oxide (NO) [14], c-GMP [8], and
potassium channel agonists [15,16] can selectively
increase capillary permeability in primary brain tumors,
while leaving normal brain unaffected. These findings
have already been translated into clinical studies to
increase drug delivery selectively to tumor tissue in brain
tumor patients [7,17-19]. Modulation of critical mole-
cules involved in selectively increasing BTB permeability
could lead to the development of effective strategy to
increase chemotherapy delivery to brain tumors.
Large conductance calcium-activated potassium (KCa)
channels are a unique class of ion channel coupling intra-
cellular chemical and electrical signaling. These channels
give rise to outwardly rectifying potassium currents and
respond not only to changes in membrane voltage, but
also to changes in intracellular calcium. Recent studies
suggest that KCa channel expression levels correlate posi-
tively with the malignancy grade of glioma [20]. KCa chan-
nels are also present in cerebral blood vessels, where they
regulate cerebral blood vessel tone [21] and, probably,
BBB/BTB permeability [15,22]. Evidence from several
studies further indicate that KCa channels play an impor-
tant role in vasodilation when it is mediated by bradyki-
nin [23,24], NO donors [25], and cyclic GMP [26]. In
response to the binding of bradykinin to its type 2 recep-
tors (B2R), intracellular Ca2+ is increased either by mobi-
lization of Ca2+ from internal sites and influx [27] or by
NO production from NO synthase activation [14]. The
increase in intracellular Ca2+ level activates KCa channels
and alters the membrane potential of cells [28]. Further-
more, previous studies have also shown that bradykinin-
induced KCa channel activation in endothelial cells is
potentiated by NS1619, a selective KCa channel agonist
[29], and attenuated by a highly selective inhibitor, iberi-
otoxin (IBTX) [29-31]. We previously demonstrated that
KCa channels are overexpressed in primary brain tumors
and tumor microvessels, and such channels respond to
NS1619, which selectively increases BTB permeability.
The accelerated formation of pinocytotic vesicles appears
to be the cellular mechanism by which KCa channels medi-
ate increases in BTB permeability [15]. Moreover, in a rat
brain tumor model, we showed that the B2R expression
level on brain tumors directly correlates with bradykinin-
induced BTB permeability increases [32]. Co-infusion of
carboplatin with either NS1619 or a bradykinin analog,
RMP-7, led to enhanced survival in intracranial tumor-
bearing rats and brain tumor patients [17-19,22,33].
These data indicate that KCa channels serve as a conver-
gence point in the modulation of BTB permeability in pri-
mary brain tumors.
Brain metastasis is a frequent complication in patients suf-
fering from lung and breast cancer, and a significant cause
of morbidity and mortality. Brain metastases are found in
approximately 10% of lung cancer patients at the time of
diagnosis, and up to 40% of all patients develop brain
metastases during the course of their disease [34]. The
prognosis of brain metastases from lung cancer is poor,
with median survival of 4~5 month. Lung cancer cells that
spread to the brain are generally sensitive to chemothera-
peutic drug compared with primary brain tumor cells. The
BTB, however, prevents the delivery of non-lipid-permea-
ble chemotherapeutic drugs and monoclonal antibodies
in sufficient amounts to achieve a therapeutic benefit
[35], especially in early stage of brain metastases.
Although metastatic brain tumors have ten times more
than the incidence of primary brain tumors in the United
States, the role and regulation of KCa channels in meta-
static brain tumors to selectively open BTB have not been
elucidated. As new therapeutic agents are developed
which effectively treat primary tumors, an efficient deliv-
ery of these agents selectively to metastatic brain tumors
across the BTB will significantly improve treatment effi-
cacy. Here, we studied the role of KCa channel activation in
BTB permeability in a metastatic brain tumor model.
Results
KCa channel mediates BTB permeability increase in a CRL-
5904 metastatic brain tumor model
To determine whether KCa channels mediate BTB permea-
bility in a metastatic brain tumor model, intracranial CRL-
5904 tumor bearing-rats received intravenous infusion of
NS1619 (0~120 μg/kg/min), bradykinin, IBTX, or PBS.
The transport constant (Ki) was determined by radiotracer
[14C] sucrose uptake in the tumor core, tumor-adjacent
brain tissue, and contralateral brain tissue. The data were
obtained from 3~6 rats for each group. Intravenous infu-
sion of NS1619 at 30 μg/kg/min resulted in a significant
increase of Ki values in the tumor center (11.24 ± 1.99 μl/Molecular Cancer 2007, 6:22 http://www.molecular-cancer.com/content/6/1/22
Page 3 of 12
(page number not for citation purposes)
g/min) as compared with PBS control (6.58 ± 0.75 μl/g/
min; p < 0.05, NS1619 vs PBS). A higher concentration of
NS1619 at 60 μg/kg/min further increased Ki  values
(12.77 ± 1.99 μl/g/min; p < 0.01, NS1619 vs PBS). While,
increasing dose to120 μg/kg/min did not elicit any further
Ki increase. Intravenous infusion of bradykinin (120 μg/
kg/min) also significantly increased BTB permeability
within the tumor, with average Ki values at 13.31 ± 2.48
μl/g/min(p  < 0.01, bradykinin vs PBS). Furthermore,
NS1619- and bradykinin- induced BTB permeability
increases resulted in enhanced delivery of radiotracer
[14C] sucrose to the tumor center without any increase to
tumor adjacent brain tissue and contralateral normal
brain (Figure 1A). In a separate experiment, we found that
co-administration of a specific KCa channel inhibitor, IBTX
(1 μg/kg/min), blocked the increase of BTB permeability
induced by NS1619 (Ki value of NS1619+IBTX is 7.58 ±
1.31 μl/g/min; NS1619+IBTX vs NS1619, p < 0.05). Intra-
venous infusion of IBTX alone did not show any effect on
BTB permeability (Figure 1B). These data confirm that
activation of KCa channel selectively induces BTB opening
in tumor tissue, but not tumor adjacent tissue or contral-
ateral normal brain, in a metastatic brain tumor animal
model.
Expression of KCa channels and B2R in CRL-5904 cells, 
HBMEC and human tumor tissue of lung cancer brain 
metastases
To examine whether KCa channels were present in tumor
tissue, immunostaining of paraffin-embedded tissue sec-
tions from lung cancer brain metastases patients were per-
formed. The results demonstrated that KCa  channels
(Figure 2A) and B2R (Figure 2B) expressed extensively in
tumor masses and microvessels within the tumor. Nega-
tive control experiments of KCa channels (Figure 2C) and
B2R (Figure 2D) did not show specific staining on the cor-
responded specimens. Elevated mRNA level of KCa chan-
nels was also detected in lung cancer brain metastases
tissues from patients using real time PCR (data not
shown). To further determine whether KCa channels and
B2Rs are present in metastatic brain tumor and endothe-
lial cells, we examined their expression by immunocyto-
chemistry. Fluorescence immunostaining showed robust
KCa channel expression in cultured CRL-5904 cells, which
distributed on the cell membrane, cytoplasm and perinu-
clear components (Figure 3A~C). KCa channels were also
detected in HBMEC (Figure 3G~I), but the signal intensi-
ties were lower compared with that in CRL-5904 cells.
B2R expression was detected in both CRL-5904 cells (Fig-
ure 3D~F) and HBMEC (Figure 3J~L) with a higher level
of expression in CRL-5904 cells. These data illustrate the
presence of KCa  channels in cultured metastatic brain
tumor cells, endothelial cells, and most importantly, in
human metastatic brain tumor tissue.
Activity of functional KCa channels in cultured CRL-5904 
cells and HBMEC
Since the above data demonstrated the presence of KCa
channels in metastatic brain tumors and endothelial cells
as well as metastatic brain tumor tissue, we determine
whether the overexpressed KCa channels were functional.
Therefore we examined membrane potential activity of
KCachannels in cultured tumor and endothelial cells and
by using a fluorescent dye-based potentiometric assay that
measures changes in membrane potential. To activate KCa
channel, NS1619 (25 μM), a KCa channel agonist, was
added to the cells, and membrane potential changes were
monitored for up to 300 seconds. Upon activation a
decrease in membrane potential was observed in CRL-
5904 cells (Figure 4A) and HBMEC (Figure 4C), an effect
that lasted more than 300 seconds. Furthermore, we intro-
duced bradykinin (25 μM) to the cultured cells and
observed membrane potential changes in CRL-5904 cells
(Figure 4B) and HBMEC (Figure 4D) that lasted for
approximately 100 seconds. Moreover, both NS1619 and
bradykinin elicited greater hyperpolarization on CRL-
5904 cells compared with HBMEC. IBTX (20 nM), a KCa
channel antagonist, reversed the membrane potential
changes on both cells caused by NS1619 and bradykinin.
Furthermore, we found that NS1619 and bradykinin
could induce a dose-dependent membrane potential
change in CRL-5904 and HBMEC (data not shown). These
data indicate that KCa channels are functional on both
CRL-5904 cells and HBMEC. The KCa channels can be acti-
vated directly by NS1619 or indirectly through B2R sign-
aling by bradykinin.
Co-culture of metastatic brain tumor and endothelial cells 
increases KCa Channel expression
We further investigated whether KCa channels expression
is modulated by the interaction of metastatic brain tumor
cells and endothelial cells. CRL-5904 cells were co-cul-
tured with HBMEC, and protein and mRNA levels of KCa
channels were examined subsequently. KCa channel were
overexpressed in CRL-5904/HBMEC co-cultures com-
pared to single cultures of either CRL-5904 cells or
HBMEC by western blot assay (Figure 5A). Image quanti-
fication analysis showed an approximately 30% increase
of KCachannel expression in co-culture of CRL-5904/
HBMEC compared to individual cultures by normalized
to β-actin as an internal control (Figure 5B). Also, individ-
ual cultures of CRL-5904 tumor cells had higher KCa chan-
nel expression than HBMEC. RT-PCR analysis also
showed an increase in KCachannel mRNA levels in co-cul-
ture cells compared to individual cultures (Figure 5C).
These data suggest that co-culture of metastatic tumor and
brain endothelial cells results in upregulation of KCa chan-
nel.Molecular Cancer 2007, 6:22 http://www.molecular-cancer.com/content/6/1/22
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Regional Ki values in metastatic brain tumor-bearing animals Figure 1
Regional Ki values in metastatic brain tumor-bearing animals. Quantitative increases in BTB permeability after biochemical mod-
ulation are shown in dose denpendent manner (A). Intravenous infusion of NS1619 (30 μg/kg/min; n = 5) significantly increased 
Ki in the tumor center compared with PBS control (p < 0.05). The optimal dose of NS1619 (60 μg/kg/min; n = 5) further 
increased Ki value (p < 0.01, NS1619 vs PBS). At higher dose (120 μg/kg/min; n = 6), however, no BTB permeability increased 
with infusion of NS1619. Intravenous infusion of BK (120 μg/kg/min; n = 3) also significantly increased Ki in the tumor center 
compared with control (p < 0.01). NS1619 (60 μg/kg/min)-induced BTB permeability increase was significantly attenuated by a 
specific KCa channels antagonist, IBTX (1 μg/kg/min; n = 4), (p < 0.05, NS1619+IBTX vs NS1619). While, intravenous infusion 
of IBTX (n = 3) alone did not show any effect on BTB permeability (B).Molecular Cancer 2007, 6:22 http://www.molecular-cancer.com/content/6/1/22
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Immuno-colocalization of KCa channel expression in a 
CRL5904 metastatic brain tumor animal model and 
human lung cancer brain metastases tissue
Since KCa channel modulators can selectively increase BTB
permeability without affecting normal brain, we wanted
to know whether KCa  channels were differentially
expressed within the tumor mass compared with normal
brain tissue. To address this question, we examined KCa
channel and endothelial cell marker von Willebrand fac-
tor (vWF) expression in CRL-5904 tumors and human
lung cancer brain metastases tissue. An abundance of
KCachannel expression (green) was detected within the
tumor mass with robust microvessel formation (red)
within the tumor area of CRL5904 tumor (Figure 6A). In
contrast, there was less KCa channel expression in normal
brain tissue adjacent to the tumor mass as well as contral-
ateral normal brain (Figure 6B). More importantly, colo-
calization of KCa channels with vWF within microvessels
was observed only within the tumor mass and not in nor-
mal brain. These results demonstrate elevated expression
of KCachannels on endothelial cells of capillaries within
the tumor mass. Immunostaining of human tissue from
lung cancer brain metastases also revealed that KCa chan-
nel expression was colocalized with vWF expression in
Expression of KCa channels and B2R in the lung cancer metastatic brain tumor tissue from patients Figure 2
Expression of KCa channels and B2R in the lung cancer metastatic brain tumor tissue from patients. KCa channels (A) and B2R 
(B) expression were detected on the tumor cells in the tissue. Negative control experiments of KCa channels (C) and B2R (D) 
did not show specific staining on the corresponded specimens by deleting of primary antibodies. Scale bar = 50 μm.Molecular Cancer 2007, 6:22 http://www.molecular-cancer.com/content/6/1/22
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Expression of KCa channels and B2R in CRL-5904 cells and HBMEC Figure 3
Expression of KCa channels and B2R in CRL-5904 cells and HBMEC. KCa channels (green) distributed in CRL-5904 cells (A~C) 
and HBMEC (G~I). The B2R (green) were expressed in CRL-5904 cells (D~F) and HBMEC (J~L). Cells were located by coun-
terstaining with DAPI (blue, B, E, H, K) and merged images are also shown (C, F, I, L). Scale bar = 50 μm.Molecular Cancer 2007, 6:22 http://www.molecular-cancer.com/content/6/1/22
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tumor capillary endothelia (Figure 6C). These results
strongly suggest that the selective BTB permeability
increase induced by modulation of KCa channel in the
metastatic brain tumor model is likely due to the overex-
presion of KCa channels on tumor cells and tumor capil-
lary endothelia.
Discussion
We have studied the presence of KCa channels and B2R in
primary brain tumors, however, their occurrence and
function in metastatic brain tumors remained to be inves-
tigated. In this study, we detected high level expression of
KCa channels in CRL-5904 tumor and brain endothelial
cells, which is consistent with previous studies showing
KCa channels expression in RG2 glioma and endothelial
cells [15]. Other investigators have also demonstrated that
the expression level of KCa channels correlates with the
malignancy grade of glioma in human [36]. Therefore,
these data suggest there is an intimate association between
KCa channel expression and brain tumor development,
which remains to be fully investigated. Additionally, we
detected the presence of B2R in CRL-5904 tumor and
endothelial cells. Liu et al also showed that B2R are
expressed in cultured RG2, C6 and 9L glioma cells, more
interestingly, the expression levels of B2R in tumor cells
was directly correlated with the increase of BTB permea-
bility induced by bradykinin in a rat glioma model [32].
Thus, the presence of KCachannels or B2R in metastatic
brain tumor cells or HBMEC may play a functional role in
BTB permeability of metastatic brain tumors.
We examined KCa channel activity on metastatic tumor
cells and capillary endothelial cells using a membrane
potential assay, which is well-correlated with the patch-
clamp method, used to measure changes in membrane
potential (FLIPR application note, Molecular devices,
CA). We found that NS1619 and bradykinin elicited
greater hyperpolarization effects on CRL-5904 than on
HBMEC. These findings may reflect a higher level of
expression for KCa channels on metastatic tumor cells as
compared to endothelial cells. Importantly, the mem-
brane potential change induced by NS1619 lasted 3 times
longer than that induced by bradykinin. These data fur-
ther support the finding, from cellular level, that NS1619-
elicited increases in BTB permeability in a glioma model
last up to 60 minutes compared to the transient effect of
bradykinin, which lasts for about 15~20 minutes [15],
partially due to B2R internalization [37]. The current data
illustrates that the presence of KCa channel are functional
in metastatic brain tumor and endothelial cells. Similar to
our findings, Reiser et al demonstrated that bradykinin
can directly activate KCa channels in rat glioma cells [38].
Other studies have shown that bradykinin can activate KCa
channels through a NO-cGMP signalling pathway [39].
Hence, our present study indicates that bradykinin-acti-
vated downstream signals, such as activation of KCachan-
nels, may be modulated to induce membrane potential
changes on brain metastatic tumor and endothelial cells.
The presence of functional KCa channels in metastatic
brain tumor and brain endothelial cells suggests that bio-
chemical modulation of KCachannels could play an
important role in therapeutic BTB opening. We further
investigated whether the KCa channels agonist, NS1619
and bradykinin could selectively enhance BTB permeabil-
ity in a metastatic brain tumor xenograft model. These
results showed that intravenous infusion of NS1619
yielded a two-fold increase the unidirectional transport of
a radiotracer into metastatic brain tumors; similar to
bradykinin-induced BTB permeability increase in meta-
static brain tumor-bearing rats. Our previous studies have
demonstrated that higher doses of intravenous bradyki-
nin are required to increase BTB permeability compared
to intracarotid infusion of bradykinin, reflecting the influ-
ence of the first pass effect with intracarotid delivery [15].
In a glioma model, it has been reported that the effects of
bradykinin on BTB permeability mediated by B2R
resulted in enhanced drug delivery to glioma [40]; and
this effect could be attenuated by coinfusion with IBTX
[15]. In this metastatic brain tumor model, we further
demonstrate the presence of B2R and confirm that the
bradykinin effect on permeability is mediated via KCa
channels. Consistent with previous studies [41], current
Measurement of functional KCa channels activity in CRL-5904  cells and HBMEC Figure 4
Measurement of functional KCa channels activity in CRL-5904 
cells and HBMEC. Membrane potential changes in relative flu-
orescence units (RFU) were detected during a 300-second 
response to 25 μM of NS1619 (A) and BK (B) respectively on 
the CRL-5904 cells. NS1619 and BK also elicited membrane 
potential changes on HBMEC (C, D). Addition of IBTX (20 
nM) reversed the membrane potential to resting values.Molecular Cancer 2007, 6:22 http://www.molecular-cancer.com/content/6/1/22
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data confirms the selective increase of BTB permeability in
brain metastatic tumors but not normal brain tissue.
These results suggest that biochemical modulation of KCa
channel induces a selective BTB opening in metastatic
brain tumor.
Confocal images showed KCa channels overexpression in
tumor tissue and tumor microvessels as compared with
normal brain. More importantly, the tumor capillaries
showed co-localization of KCa channels and vWF in tumor
area of CRL-5904 tumor and in human metastatic brain
tumor tissue. To further study the interaction between
tumor and endothelial cells, we co-cultured CRL-5904
metastatic brain tumors and brain endothelial cells. We
show that mRNA expression of KCa channels is upregu-
lated in co-cultured cells compared to indivdual cultures.
These data suggest that increased KCa channel expression
and their activity in tumor endothelial cells maybe due to
the tumor micro-environment or cell-to-cell communica-
tion between tumor and microvessel endothelial cells.
This is consistent with reports that brain tumor cells
increase KATP channel expression in endothelial cells[16].
These findings support a pivotal role for KCa channels in
BTB permeability regulation. Recently clinical study
showed that trastuzumab, anti-HER2 antibody, while
effective in treating tumors outside the brain, fails to treat
brain metastases due to its inability to cross the blood
brain tumor barrier [42]. Our research has shown that
KCachannel-mediated BTB permeability modulation
could be a useful strategy to increase therapeutic agents,
such as antibody-based therapies, delivery into metastatic
brain tumors.
Conclusion
We present evidence that activation of KCa channels by a
channel-specific agonist can selectively enhance BTB per-
meability in a metastatic brain tumor rat model. We show
KCa channel and B2R are highly expressed in brain meta-
static tumor cells, endothelial cells and lung cancer brain
metastatic tissue. The expression level is correlated with
KCa channel activity in these cells. In a metastatic brain
tumor model, we demonstrate that NS1619 and bradyki-
nin can selectively open BTB and significantly enhance the
radiotracer delivery specifically to metastatic brain
tumors. It is also demonstrated that KCa channels expres-
sion can be upregulated in the co-cultures of tumor cells
and endothelial cells, as well as in the microvessel
endothelia of brain metastases tissue. KCachannels may be
exploited as specific target for selectively pharamacologic
modulation of BTB to increase delivery of chemothera-
peutic drugs to brain metastases.
Methods
Cell Culture
CRL-5904 cells (human non-small cell lung cancer; meta-
static site: brain poorly differentiated carcinoma) and
human brain microvessel endothelial cells (HBMEC)
were obtained from the American tissue culture collection
(ATCC, VA) and maintained in RPMI 1640 with 10% fetal
bovine serum. Both cell lines were maintained in the com-
Modulation of KCa channel expression in co-cultured cells  (CRL-5904 cells and HBMEC) Figure 5
Modulation of KCa channel expression in co-cultured cells 
(CRL-5904 cells and HBMEC). Western blot analysis for KCa 
channel expression on cultured cells. Lane1, CRL-5904 cells; 
Lane 2, CRL-5904 and HBMEC co-culture; Lane 3, HBMEC 
(A). Semi-quantitative analyses of the protein bands were 
normalized by internal control, β-actin (B). mRNA transcrip-
tion levels of different cell cultures were determined by RT-
PCR. L: 1 kb ladder; Lane1, CRL-5904 cells; Lane 2, CRL-
5904 and HBMEC co-culture; Lane 3, HBMEC (C).Molecular Cancer 2007, 6:22 http://www.molecular-cancer.com/content/6/1/22
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mon tissue culture condition. For co-culture of CRL-5904
cells with HBMEC, the same number of CRL-5904 cells
and HBMEC were co-cultured in growth medium and
allowed to achieve 90% confluence. Then, the co-culture
and single cultures of cells were harvested for protein or
RNA extraction.
Membrane Potential Assay
The functional activity of KCa channels in CRL-5904 cells
and HBMEC was measured using the FLIPR Membrane
Potential Assay Kit on a FLEXstation (Molecular Devices,
Sunnyvale, CA) as described previously [15]. This kit pro-
vided a fast, simple and consistent mix-and read proce-
Localization of KCa channels in brain tumor tissues from xenogenic rat model and patients of lung cancer brain metastases Figure 6
Localization of KCa channels in brain tumor tissues from xenogenic rat model and patients of lung cancer brain metastases. KCa 
channels (green) were localized in the endothelial cells of capillaries (red) in the tumor mass (A). In the contralateral side of 
brain, much less of KCa channel was detected in normal brain. (B). KCa channels are co-localized with von Willebrand factor, a 
marker of endothelial cells, in human tumor tissue of lung cancer brain metastases (C). Scale bar = 250 μm.Molecular Cancer 2007, 6:22 http://www.molecular-cancer.com/content/6/1/22
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dure. In brief, the cells were seeded in sterile, clear
bottom, black 96-well plates (Corning Inc., MA) at den-
sity of 2 × 103 cells/well to achieve monolayer within 24
h. The monolayer cells were incubated with the mem-
brane potential assay kits reagents for 30 min before load-
ing the compounds. The anionic potentiometric dye that
transverses between cells and extracellular solution in a
membrane potential-dependent manner serves as an indi-
cator of vasomodulator-induced voltage changes across
the cell membrane. Dose response studies were per-
formed with 0 to 50 μM NS1619 or bradykinin with or
without IBTX (20 nM). The FLEXstation was set up using
the following parameters: excitation 530 nm, emission
565 nm, and emission cut of 550 nm wavelengths. Obser-
vations and recordings were made for 300 seconds after
adding the compounds. NS1619, bradykinin and IBTX
were obtained from Sigma (St. Louis, MO).
In Vivo BBB/BTB Permeability
All of the animals used were conducted in accordance
with the Institutional Animal Care and Usage Committee
in force at Cedars-Sinai Medical Center. A metastatic brain
tumor xenograft model was established using athymic
nude rats (180–200 g; Charles River Laboratories, Inc.,
MA) for BBB/BTB permeability studies. Athymic nude rats
were anesthetized with i.p. ketamine and xylazine, and
stereotactically implanted with CRL-5904 cells (2 × 105)
in 4 μl of 1.2% methylcellulose/PBS using a Hamilton
syringe into the right striatum. The Coordinates were 3.4
mm lateral to bregma and 5.0 mm deep from dura. Ten
days after tumor implantation, the femoral arteries of rats
were cannulated to measure blood pressure and collect
blood, and the femoral vein was also cannulated to
administer the drugs and radiotracer. Body temperature
was maintained at 37°C. Arterial blood gases, blood pres-
sure and hematocrit were monitored. Animals with
abnormal physiological parameters were eliminated from
this study. In regional permeability studies, either intrave-
nous drug or PBS was infused into the femoral vein at a
rate of 66.7 μl/min for 15 minutes. Five minutes after the
start of the intravenous infusion, 50 μCi/kg of the radi-
otracer [14C] sucrose was injected as an intravenous bolus.
Arterial blood pressure was monitored throughout the
experimental period with a blood pressure monitor
(DigiMed, KY). The unilateral transport constant Ki (μl/g/
min), which is an initial rate for blood-to-brain transfer of
radiotracer, was calculated as described by Ohno et al[43].
The Ki was determined by radiotracer [14C] sucrose in the
tumor core, tumor-adjacent brain tissue, and contralateral
brain tissue using the quantitative autoradiographic
(QAR) method as describe previously [44]. Quantitative
analysis of the regional radioactivity was performed using
a computer (Power Macintosh 7100) and Image 1.55 soft-
ware (National Institutes of Health, Bethesda, MD). An
optimum dose (120 μg/kg/min, i.v.) of bradykinin estab-
lished previously was used for Ki measurements. To estab-
lish the optimal and safe dose range that would result in
selective increase in BTB permeability without appreciably
altering system blood pressure, various doses (0~120 μg/
kg/min, i.v.) of NS1619 were administered in metastatic
brain tumor bearing-nude rats. Additional experiments
were performed by coinfusing of NS1619 with IBTX (1.0
μg/kg/min) to investigate whether inhibition of KCa chan-
nels by IBTX has any effects on NS1619-induced permea-
bility increase.
Western Blot Analysis
The extracted protein samples were quantified to deter-
mine total protein concentrations using a protein assay kit
(BioRad, CA). Same amount of each sample was fraction-
ated on 10% SDS-polyacrylamide gel and then transferred
to a nitrocellulose membrane. The membrane was probed
with primary antibodies anti-MaxiKá (1:200; Santa Cruz
Biotechnology, CA) and β-actin (1:5000; Sigma, MO), fol-
lowed by peroxidase-conjugated secondary antibodies.
The signals were detected with an enhanced chemilumi-
nescence kit (Amersham Biosciences Corp., NJ). β-actin
served as an internal control.
Reverse Transcription-PCR
The extracted RNA was reverse transcripted using a Bio-
script kit (Bioline) and Oligo (dT) 12–18 primer (Invitro-
gene). The resulting cDNA products were used as
templates for PCR assay. The genes of the KCa channels
were concurrently amplified with internal control β-actin
in the same reaction tube as described previously [45].
Sequence specific primers were used for amplification of
KCa channels (forward: 5'-tccaaaacaaccaggctctc-3'; reverse:
5'- gggggagatgttgtgaagaa-3') and β-actin (forward: 5'- gcac-
cacaccttctacaatgagc-3'; reverse: 5'- ttgaaggtagtttcgtggatgcc-
3'). PCR products were identified using agarose gel elec-
trophoresis and ethidium bromide staining.
Immunocytochemistry Staining
CRL-5904 cells and HBMEC were fixed with 4% parafor-
moldehyde for 15 min, and then incubated with anti-B2R
(1:200; BD Bioscience, NJ) or anti-MaxiKα (1:200; Santa
Cruz, CA) antibodies. The signals were detected with
FITC-conjugated secondary antibodies (1:200; Jackson
ImmnoResearch, CA). The cells were counterstained with
4', 6-diamidino-2-phenylindole (DAPI; Vector Laborato-
ries, CA) and cover-slipped. Paraffin-embedded, meta-
static brain tumor samples from lung cancer were
deparaffinized and rehydrated. The slides were incubated
with primary anti-MaxiKá and anti-B2R antibodies, and
followed by biotinylated secondary antibodies (1:1000;
Jackson ImmunoResearch, CA). Biotinylated conjugates
were detected with avidin-biotin peroxide complex (Vec-
tor Laboratories), and then developed with 3, 3'-Diami-
nobenzidine (DAB) method. The sections wereMolecular Cancer 2007, 6:22 http://www.molecular-cancer.com/content/6/1/22
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counterstained with hematoxylin. For the double stain-
ing, the sections were incubated with primary antibodies,
anti-MaxiKá and anti-von Willebrand Factor (1:200;
Chemicon, CA), and then subjected to FITC-and Tex-Red-
conjugated secondary antibodies. The slides were exam-
ined under confocal microscopy. Negative control experi-
ments were performed on all the corresponded specimens
by deleting of primary antibodies.
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